Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
FFS this is dire. Not a word from Stamp since the RNS either. Pathetic management
might need to pump the sp to get folk onboard - perhaps Janssen will provide an endorsement
The most imortant reason why $MTP bought bioaf is because it is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB)
FFS
Bioasis, with a market cap tonight of CDN $11.5 million, is being bought by a company that goes to bed tonight with a market cap of only about CDN $6 million, and Bioasis shareholders end up with less than 10% of the resulting company.
Together, current Midatech and Bioasis shareholders will end up with less than 50% of the resulting company, meaning that control of the resulting company goes, it appears, to investors brought to the table by Ladenburg Thalmann.
The resulting company can do anything it wants without a single vote from current Midatech and Bioasis shareholders, including selling the company to private concerns, or selling xB3 to private concerns and running the Midatech/Bioasis combination on Cresence EGF stuff.
It looks to me like the current Midatech shareholders are just about as exposed as Bioasis shareholders are.
2.6p is annihilation for all LTH's. I averaged down to 15p and was licking my wounds at 6p but this feels like the end of the road - if he is so happy about the deal and the prospects this creates he needs to start telling the story. Surely he needs to if it requires shareholder approval to proceed?
What's the market cap of the new company?
How much cash?
Does it have the financial wherewithal, scientific teams, and clinical trial infrastructure to advance on its own with the other clinical stage assets and to enter more substantial strategic alliances, etc.
How can the various technology be used together?
How undervalued was the other company itself helping to offset some of the undervaluation to Mtph?
Midatech has been unable to advance for years. Is this new company now viable with cash, clinical trial infrastructure, newsflow from multiple clinical assets, and a NASDAQ listing, etc.?
Do you see this as a good deal? Currently $1.10 in US
read the RNS - this was last chance saloon for Stamp - if this deal doesn't get approval the company will likely fold. I don't need to deramp this, Stamp has done a great job. One minute we were all about 'partnerships' now we are buying other companies for more money than we are worth ourselves!
... this is approved - Stamp is trying to promote this as a win, and it is - for him and and new shareholders. I will take years for the SP to recover to any reasonable level and AIM traders will now have to transfer to US ADR's in the process. Stamp needs to get an interview set up to explain to the markets why he is so happy. The rest of us are not
Am I missing something here? Stamp is selling this as some amazing deal but long term holders have been shafted
Part 2! SP at another all time low...
https://twitter.com/Midatech/status/1592452920121110529?t=q6cido2FsykR2bfZtHHSeQ&s=19
…
This is being walked down.
… wonder how this week’s meetings have gone?
Exactly! Hindsight has 20/20 vision…
Riight… so you would rather have uneducated folk working at the BoE? They are busy trying to keep up with the damage of Tory policies…
You clearly have an issue with knowledge, hence your original comment.
Thanks for your uneducated opinion